GlassScriptPhysician profile
Georgiana Nuss
NPI 1023428505
$4,273.48
in general payments reported to CMS, 2019-2025
28 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $192 · 2021: $827 · 2022: $494 · 2023: $694 · 2024: $1,231 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,981.83 |
| Education | $190.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $621.39 | 2021-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $618.80 | 2019-2025 | Uzedy |
| Otsuka America Pharmaceutical, INC. | $460.34 | 2019-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $380.96 | 2019-2025 | Lybalvi, Aristada |
| Abbvie INC. | $369.35 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $208.23 | 2019-2025 | Trintellix |
| Lundbeck LLC | $148.16 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $144.10 | 2020-2021 | |
| Corium, LLC | $144.10 | 2023-2025 | Azstarys |
| Shire North American Group INC | $112.98 | 2019 | |
| Avanir Pharmaceuticals, INC. | $110.99 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $108.40 | 2021-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $107.92 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $101.80 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $95.00 | 2024 | Cobenfy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $94.43 | 2022-2023 | Quviviq |
| Tris Pharma INC | $79.02 | 2024 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $58.57 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $54.38 | 2021-2023 | Belsomra |
| Eisai INC. | $37.76 | 2021 | |
| Acadia Pharmaceuticals INC | $35.04 | 2022 | |
| Neos Therapeutics, LP | $31.36 | 2020 | |
| Ironshore Pharmaceuticals INC. | $30.72 | 2019 | |
| Vertical Pharmaceuticals, LLC | $28.19 | 2019 | |
| Almatica Pharma LLC | $26.59 | 2021-2022 | |
| Biogen, INC. | $24.71 | 2021 | |
| Axsome Therapeutics, INC. | $22.71 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgiana Nuss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.